Madrigal Pharmaceuticals, Inc.
MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor- agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steaā¦ read more
Healthcare
Biotechnology
18 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$430.11
Price-4.15%
-$18.62
1Y
Price
Market Cap
$9.587b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-18.2%
EBITDA Margin-19.9%
Net Profit Margin-22.1%
Free Cash Flow MarginRevenue
$515.547m
+186.2%
1y CAGR+62.1%
3y CAGR+46.6%
5y CAGREarnings
-$281.899m
+39.5%
1y CAGR-3.9%
3y CAGR-8.5%
5y CAGREPS
-$12.64
+42.3%
1y CAGR+5.6%
3y CAGR-0.3%
5y CAGRBook Value
$695.978m
$1.015b
Assets$319.403m
Liabilities$123.949m
DebtDebt to Assets
12.2%
-0.5x
Debt to EBITDAFree Cash Flow
-$308.387m
+32.5%
1y CAGR-17.5%
3y CAGR-18.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company